Everest Medicines and Providence Therapeutics have reported that their Covid-19 vaccine, PTX-COVID19-B, obtained approval to be part of the World Health Organization (WHO) Solidarity Trial Vaccines (STV) programme.

The inclusion comes after a recommendation from an independent advisory group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A messenger ribonucleic acid (mRNA) vaccine, PTX-COVID19-B encodes the SARS-CoV-2 S protein encapsulated in a lipid nanoparticle.

The global, randomised STV clinical trial is assessing the efficacy and safety of potential Covid-19 vaccine candidates.

Based on pre-defined eligibility requirements, an independent vaccine prioritisation advisory group chooses the vaccines.

The criteria features a vaccine’s safety, its potential for efficacy, stability, ease of manufacturing for global supply and administration.

Sponsored by and funded by the WHO, the trials are currently enrolling subjects in selected study centres in the Philippines, Mali and Colombia.

The panel has so far reviewed the data from nearly 20 vaccines and included two vaccines of Medigen and Inovio, respectively, in the trial.

Individuals of the age 16 years and above residing in regions with greater Covid-19 incidence rates but were not infected or have not been inoculated form part of the trial.

All subjects in the trial will be followed up weekly for a minimum of one year on receiving the vaccines.

Everest Medicines CEO Kerry Blanchard said: “The STV trial complements the joint efforts of Everest and Providence in generating a robust safety and immunogenicity data set design.

“We hope this can help accelerate approval with regulatory bodies around the world.”

According to interim results from the Phase I trial of PTX-COVID19-B, the vaccine was found to offer robust virus neutralisation ability and induced antibodies levels in line with already approved Covid-19 mRNA shots.

Furthermore, treatment with PTX-COVID19-B was found to be safe and well-tolerated in the trial.

In September this year, Everest and Providence entered a definitive agreement to licence rights to the latter’s mRNA Covid-19 shots in some emerging markets in Asia.